{
    "nct_id": "NCT04417530",
    "official_title": "A Phase 2 Open-label, Ascending Single and Repeat Dose Escalation Trial of Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma",
    "inclusion_criteria": "* Clinical diagnosis of primary indeterminate lesion or small choroidal melanoma (IL/CM)\n* Have no evidence of metastatic disease confirmed by imaging\n* Be treatment na√Øve for IL/CM\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have known contraindications or sensitivities to the study drug or laser\n* Active ocular disease",
    "miscellaneous_criteria": ""
}